3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Terminated
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
64
Neoplasm Metastasis
25
Kidney Neoplasms
21
Neoplasms
16
Breast Neoplasms
15
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Prostatic Neoplasms
10
Lung Neoplasms
8
Brain Neoplasms
8
Melanoma
7
Colorectal Neoplasms
7
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Neuroendocrine Tumors
6
Liver Neoplasms
6
Glioblastoma
6
Gastrointestinal Stromal Tumors
6
Carcinoma, Hepatocellular
6
Thyroid Neoplasms
5
Thymoma
5
Small Cell Lung Carcinoma
5
Recurrence
5
Multiple Myeloma
5
Esophageal Neoplasms
5
Carcinoma
5
Uveal Melanoma
4
Stomach Neoplasms
4
Sarcoma
4
Adenocarcinoma
4
Interventions
durvalumab
5
Nivolumab
3
Cyclophosphamide
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
padeliporfin
2
anlotinib
2
Trabectedin
2
Sunitinib
2
Pemetrexed
2
Docetaxel
2
Chemoradiotherapy
2
Carboplatin
2
Bevacizumab
2
sotorasib
1
relatlimab
1
relacorilant
1
pembrolizumab
1
patritumab
1
palbociclib
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
golotimod
1
genexol-PM
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms by Site
×
Sunitinib
×
Clear all
NCT01215578
2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
33 enrolled
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled